Alzheimer's disease

Neurotechnology company Cognito Therapeutics scores $73M to study Alzheimer's device
Neurotechnology company Cognito Therapeutics scores $73M to study Alzheimer's device
Mobihealthnews
Cognito Therapeutics
Alzheimer's disease
Medtech
funding
neuromodulation
Flag link:
Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
PM Live
Roche
Eli Lilly
Alzheimer's disease
diagnostics
Flag link:
Despite CMS snub, Eisai is 'not so nervous' about Leqembi's long-term coverage prospects: US CEO
Despite CMS snub, Eisai is 'not so nervous' about Leqembi's long-term coverage prospects: US CEO
Fierce Pharma
Eisai
Leqembi
FDA
CMS
Alzheimer's disease
Flag link:
Alzheimer's Association campaigns for broader Leqembi coverage: report
Alzheimer's Association campaigns for broader Leqembi coverage: report
Fierce Pharma
CMS
Eisai
Biogen
Leqembi
Alzheimer's disease
Flag link:
Biogen's head of neurodegeneration leaves
Biogen's head of neurodegeneration leaves
Fierce Biotech
Biogen
women executives
Aduhelm
Alzheimer's disease
Flag link:
VA to cover Eisai's new Alzheimer's drug after declining to cover Aduhelm
VA to cover Eisai's new Alzheimer's drug after declining to cover Aduhelm
Endpoints
VHA
Eisai
Biogen
Leqembi
Aduhelm
Alzheimer's disease
Flag link:
Eisai projects $7B in sales by 2030 for new Alzheimer's drug
Eisai projects $7B in sales by 2030 for new Alzheimer's drug
Endpoints
Eisai
Biogen
Alzheimer's disease
Leqembi
Flag link:
Lilly’s Alzheimer’s struggles continue as preclinical asset fails phase III
Lilly’s Alzheimer’s struggles continue as preclinical asset fails phase III
BioSpace
Eli Lilly
Alzheimer's disease
solanezumab
clinical trials
Flag link:
Researchers announce highly accurate blood test for Alzheimer's Disease
Researchers announce highly accurate blood test for Alzheimer's Disease
Drugs.com
Durin Technologies
diagnostics
Alzheimer's disease
Flag link:
FDA sets July decision date for full approval of Leqembi
FDA sets July decision date for full approval of Leqembi
BioSpace
Eisai
Biogen
Alzheimer's disease
Leqembi
FDA
lecanemab
Flag link:
ICER dials up recommended price range for Eisai's Leqembi—but still calls for sizable discount
ICER dials up recommended price range for Eisai's Leqembi—but still calls for sizable discount
Fierce Pharma
ICER
Eisai
Leqembi
drug pricing
Alzheimer's disease
Flag link:
Despite recent approvals, significant unmet need remains in Alzheimer’s market
Despite recent approvals, significant unmet need remains in Alzheimer’s market
Clinical Trials Arena
Alzheimer's disease
Biogen
Eisai
Lundbeck
Otsuka
Avanir Pharmaceuticals
Axesome
Aduhelm
Leqembi
Flag link:
Acumen reveals late-stage clinical trial plans in early Alzheimer’s disease
Acumen reveals late-stage clinical trial plans in early Alzheimer’s disease
Clinical Trials Arena
Acumen Pharmaceuticals
clinical trials
Alzheimer's disease
ACU193
monoclonal antibodies
Flag link:
Axsome says FDA wants more data for Alzheimer’s agitation label expansion, but readout to come sooner 
Axsome says FDA wants more data for Alzheimer’s agitation label expansion, but readout to come sooner 
Endpoints
Axsome Therapeutics
FDA
clinical trials
Alzheimer's disease agitation
Alzheimer's disease
AXS-05
Flag link:
Medicare maintains limits on Eisai’s new Alzheimer’s drug
Medicare maintains limits on Eisai’s new Alzheimer’s drug
BioPharma Dive
Medicare
CMS
Eisai
Biogen
Leqembi
Alzheimer's disease
Flag link:
Eisai Anticipates Full Approval of Leqembi as Early as July
Eisai Anticipates Full Approval of Leqembi as Early as July
BioSpace
Eisai
FDA
Alzheimer's disease
Leqembi
lecanemab
Flag link:
Biogen chairman to step down as new CEO walks thin line with Alzheimer's launch Leqembi
Biogen chairman to step down as new CEO walks thin line with Alzheimer's launch Leqembi
Fierce Pharma
Biogen
Chris Viehbacher
Stelios Papadopoulos
Pharma CEOs
Alzheimer's disease
Leqembi
Flag link:
FDA adds warning of 'larger areas of bleeding' in brain to Biogen's Aduhelm label
FDA adds warning of 'larger areas of bleeding' in brain to Biogen's Aduhelm label
Endpoints
Biogen
Aduhelm
FDA
Alzheimer's disease
Flag link:
Eisai gives first glimpse into Alzheimer’s drug launch
Eisai gives first glimpse into Alzheimer’s drug launch
BioPharma Dive
Eisai
Alzheimer's disease
drug launches
Leqembi
Flag link:
Prothena: Trial data underscores the potential of antibody in treating Alzheimer’s disease
Prothena: Trial data underscores the potential of antibody in treating Alzheimer’s disease
Biopharma Reporter
Protena
clinical trials
Alzheimer's disease
PRX005
Flag link:

Pages